Skip to main content

Table 1 Baseline demographics and clinical characteristics of patients a

From: Peroxisome proliferator-activated receptor γ agonist effect on rheumatoid arthritis: a randomized controlled trial

Demographics and characteristics

Data

Demographics and anthropomorphic measures

 Age (years)

51.0 (±14.2)

 Females (%)

82.4% (28)

 Race, Caucasians (%)

85.3% (29)

 Weight (kg)

77.3 (±18.1)

 BMI (kg/m2)

28.28 (±6.04)

Disease-related and laboratory indices

 DAS28-CRP (units)

4.58 (±1.10)

 Tender joints (n)

9.68 (±6.96)

 Swollen joints (n)

8.38 (±4.66)

 VAS (mm)

43.0 (±28.5)

 CRP (mg/dl)

12.69 (±24.57)

 ESR (mm/h)

22.8 (±21.3)

 HOMA (units)

3.11 (±2.68)

Current medication use

 Methotrexate (%)

70.6% (24)

 Leflunomide (%)

14.7% (5)

 Sulfasalazine (%)

2.9% (1)

 Hydroxycholorquine (%)

17.6% (6)

 Biologic (%)

52.9% (18)

 Corticosteroid (%)

52.9% (18)

  1. aData are presented as mean (±SD) for continuous data and percentage (number) for categorical variables. BMI, body mass index; CRP, high-sensitivity C-reactive protein; DAS28-CRP, Disease Activity Score in 28 joints high-sensitivity C-reactive protein; ESR, erythrocyte sedimentation rate; HOMA, homeostatic model assessment of insulin resistance; VAS, Visual Analogue Scale for Global Health.